Say It Yourself — How Disclosing Limitations, Uncertainty, and Conflicts of Interest Builds Trust

There will always be moments when staying quiet feels easier. An inconvenient data point. A cited researcher's conflict of interest. A safety profile that hasn't been fully characterized. Speaking up feels like it undercuts the material. But the record shows the opposite: trust collapsed precisely when disclosure didn't happen. Transparency is not weakness. Only those who handle evidence with integrity earn trust that lasts.

So What / So Why — Why This Principle Matters

What pharmaceutical materials deliver to physicians is information. What physicians actually receive, though, is the basis on which they decide how far to trust that information. Even when efficacy data are accurate, if a cited author's financial relationship with the manufacturer goes unmentioned, the physician has no way to assess potential bias. If a negative result in a Japanese patient subgroup is absent from the material, the physician makes a prescribing decision on a map with pieces missing. What a material author chooses not to say shapes prescribing just as much as what they do say.

The Ministry of Health, Labour and Welfare's promotional information monitoring program has spent seven years documenting how the absence of transparency shows up in practice. A COI slide displayed briefly enough to vanish before it registers. Safety information reduced to a ten-second projection of the package insert at the end of a twenty-minute seminar. A video citing a safety study whose lead author was on a paid medical advisory board for the manufacturer — with no disclosure anywhere in the footage. None of these were lies. They were simply things left unsaid. Yet the monitoring reports recorded each one as a violation. Seven years of evidence establish a clear principle: omission is also a violation.

The March 2025 Survey Project report (Document No. 001520054) recorded that over the nine-month monitoring period in Reiwa 6, suspected violations were identified for 18 drugs across 23 violation items. Inappropriate promotional activity continues to recur even after eight years of monitoring.

The reason a material author should maintain transparency comes before regulatory compliance. For patients to receive drugs safely, physicians must make prescribing decisions on accurate information. Protecting that premise — stating inconvenient facts without waiting to be asked — is what the work of material authorship is actually about.

Principles — The Standard to Hold

I want to be a steward of evidence, not a persuader. Believing in the value of a product and honestly stating its limits are not in conflict. The materials I create sit on a physician's desk when a prescribing decision is being made. If there are facts I didn't put there, the physician's judgment rests on an incomplete map from the start.

COI gets disclosed — by me, without prompting. If an author cited in my material has received payment from a pharmaceutical company, that fact goes into the material. Disclosure does not diminish the paper's value. It gives the reader what they need to form their own judgment. Burying a COI in a slide timed to disappear is preserving the form while abandoning the purpose. If you're disclosing, disclose in a form people can actually read.

Uncertainty gets stated plainly. If data in a Japanese patient subgroup are negative, that gets written down. If no head-to-head trial exists, I say so. "Mechanism of action suggests it should be safe" is a hypothesis, not evidence. Presenting uncertain conclusions as settled is the first step toward losing integrity.

I can build a material while fully aware of its limits — that doesn't mean waiting until every data point exists. It means representing what is known accurately and what is unknown honestly. Doubt is real: I think about how a supervisor or a sales colleague might react when they see an inconvenient fact written out. Choosing to write it anyway, each time, is what it means to do this work with integrity.

Daily Practice — Specific Actions and Checks

Transparency is not an abstract commitment. It shows up as specific language somewhere in the material. Below are practices that can start tomorrow.

• Place COI disclosures immediately after citations. Add a sentence — "Among the authors, N individuals have received research support or speaker fees from the manufacturer of this product" — as a footnote to each cited paper. Match the font size to body text.
• State explicitly what the data cannot support. After presenting efficacy data, add a sentence such as: "This trial enrolled [population]; effectiveness in Japanese patients requires separate confirmation." The standard is not whether something was written — it is whether the physician reading it understood.
• Name the risks listed in the RMP. Important potential risks documented in the Risk Management Plan should appear as written language in the safety section. Directing readers to "see the package insert" is structurally the same as omitting the information.
• Ask yourself: would a physician's decision change if they knew this? Use this question in final review. If the answer is yes, there is a fact not yet on the page.
• Ask yourself: can a physician actually read the COI disclosure? Check whether the footnoted COI information is legible given font size, display duration, and placement. "It's in there" and "it was received" are different things.
• Don't relegate negative data to an appendix. Tucking an unfavorable subgroup result or a limitations statement into the back of a document in small type is structural omission. Find a place for it in the body.

When It Gets Hard — Under Pressure

Two weeks from a quarterly deadline, the question surfaces: does this COI disclosure really have to be in here? A colleague in sales mentions that a physician might hesitate when they see this section. A deadline pushes a decision into "we'll address it in the next revision." None of this is unusual. These are the decision points every material author encounters.

The monitoring records show a pattern in how transparency gets eroded. The March 2021 monitoring report includes a speaker's explanation that a COI disclosure was not made because the organizer had not requested one. Behind the phrase "was not requested" is someone who chose not to speak. The psychology that enabled that choice is called externalization of responsibility — attributing the origin of one's own action to someone else, releasing oneself from accountability for the choice (the structure of this pressure is examined in detail in "When It Gets Hard" series, Vol. 9).

Drawing a line in advance makes it easier to hold under pressure. COI disclosures go in, readable. Negative data don't get cut. Limits appear in the body text. With those three rules set as personal policy, each individual situation no longer requires a fresh judgment call. It narrows the space for the reasoning that says "just this once."

When pressure comes from management or sales, the language of the guidelines is available to borrow. "Provide information on efficacy and safety based on scientific and objective evidence" — "provide negative information as well" — these are not one person's preferences. They are the principles the Ministry of Health, Labour and Welfare's guidelines set out. Drawing on the language of a public standard, rather than a personal opinion, makes it possible to hold a position under pressure without making it personal.

Grounding — What to Return to When It Gets Difficult

When the choice to speak up becomes hard to sustain, return to the question of what actually happens when disclosure doesn't occur.

What happens when COI is not disclosed? The March 2019 Advertising Activity Monitoring Project report documents a case in which the lead author of a safety study cited in a product video was receiving payment as a medical affairs advisor for the manufacturer of that product, with no disclosure anywhere in the video. Physicians received the study as neutral scientific evidence. But that evidence carried potential bias. By withholding the COI disclosure, the author removed one piece of information physicians needed to form their judgment. (The structure of this pressure is examined in detail in Series 1, Vol. 8: "Undisclosed Conflicts of Interest".)

What happens when safety information is withheld? A twenty-minute seminar dwelling on efficacy, followed by a ten-second projection of the package insert at the close — recorded in the March 2020 monitoring report — technically "provided safety information," but nothing reached the physicians. "Not saying" is the counterimage against which the commitment to speak up defines itself. (See Series 1, Vol. 5: "The Choice Not to Say — The Sin of Omission.")

The Guidelines on Sales Information Provision Activities for Prescription Drugs set out the basic principle as providing information on efficacy and safety "based on scientific and objective evidence." Requiring transparency on conflicts of interest follows from the same logic. This is a condition for integrity as someone who delivers medical information, before it is a regulatory obligation.

When I take a material I have built into a physician's office, if a fact not on those pages could change how they prescribe, the responsibility to write it down is mine. There is no need to wait until someone asks. Speaking up without being prompted is the spine of this work.